Growth Metrics

Haemonetics (HAE) Capital Expenditures (2016 - 2025)

Haemonetics has reported Capital Expenditures over the past 17 years, most recently at $6.3 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 25.71% year-over-year to $6.3 million; the TTM value through Dec 2025 reached $30.8 million, up 1.46%, while the annual FY2025 figure was $39.3 million, 3.02% up from the prior year.
  • Capital Expenditures for Q4 2025 was $6.3 million at Haemonetics, up from $5.0 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $93.1 million in Q2 2023 and troughed at $3.8 million in Q2 2025.
  • A 5-year average of $19.6 million and a median of $12.8 million in 2021 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 226.65% in 2022 and later crashed 92.82% in 2024.
  • Year by year, Capital Expenditures stood at $20.8 million in 2021, then decreased by 19.05% to $16.8 million in 2022, then fell by 13.07% to $14.6 million in 2023, then plummeted by 41.65% to $8.5 million in 2024, then fell by 25.71% to $6.3 million in 2025.
  • Business Quant data shows Capital Expenditures for HAE at $6.3 million in Q4 2025, $5.0 million in Q3 2025, and $3.8 million in Q2 2025.